Parkinson’s Disease

Adams JD Jr., Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer’s and Parkinson’s disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Molecular Chemistry Neuropathology 14(3);213-226, 1991 Medline

Adams JD Jr., Odunze IN. Oxygen free radicals and Parkinson’s disease. Free Radical Biol Med 10(2):161-169, 1991 Medline

Di Monte DA, Chan P, Sandy MS. Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage? Annals of Neurology 32(suppl):S111-115, 1992 Medline

Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson’s disease. Progress in Neurobiology 48(1): 1-19, 1996 Medline

Gabby M, Tauber M, Porat S, Simantov R. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology 35(5):571-578, 1996 Medline

Jenner P. Oxidative damage in neurodegenerative disease. Lancet 17:796-798, 1994 Medline

Jenner P. Oxidative stress in Parkinson’s disease and other neurodegenerative disorders. Pathol Biol 44(1):57-64, 1996 Medline

Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47(6 suppl3):S161-S170, 1996 Medline

Owen AD, Schapira AHV, Jenner P, Marsden CD. Oxidative stress and Parkinson’s disease. Annals of the New York Academy of Science 786:217-223, 1996 Medline

Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Experimental Neurology 141(1):32-39, 1996 Medline

Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral GSH deficiency? Neuroscience Letter 33(3):305-310, 1982 Medline

Reiderer P, Sofic E, Rausch WD, Schmidt B. Transition metals, ferritin, GSH, ascorbic acid in Parkinsonian Brains. Journal of Neurochemistry 52:515-520, 1989 Medline

Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 20(7):1159-70, 1996 Medline

Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson’s disease. Annals of Neurology 36(3)356-361, 1994 Medline

Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology 36(3):348-355, 1994 Medline

Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annual Review of Pharmacology & Toxicology 36:83-106, 1996 Medline 

Spencer JP, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-Dopa and dopamine. Relevance to Parkinson’s disease. Neuroreport 6(11): 1480-84, 1995 Medline

Zhang F. Dryhurst G. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson’s disease. Journal of Medical Chemistry 37(8);1084-98, 1994 Medline